MAPT and Alzheimer disease: A study conducted at the Los Angeles Longevity Institute shows that periodic protein restriction cycles, without CR, in mice already displaying significant cognitive impairment and Alzheimer's disease (AD)-like pathology can promote changes in circulating growth factors (reduction of IGF-1 and increase of IGFBP-1) as well as decrease of tau phosphorylation in the hippocampus with a consequent reduction of the age-dependent impairment in cognitive performance [82].